Abstract
There is a growing body of evidence that the formation and accumulation of advanced glycation end products (AGE) have been known to progress under diabetic conditions, thereby being involved in diabetic vascular complications. Further, we, along with others, have recently found AGE could disturb insulin actions in cultured adipocytes and skeletal muscles. However, the pathological role of AGE in insulin resistance in vivo is not fully understood. Therefore, in this study, we examined whether pyridoxamine, an inhibitor of AGE formation could ameliorate insulin resistance in KK-Ay mice, a model animal of obese, type 2 diabetes. Fasting blood glucose, serum levels of insulin and AGE in KK-Ay mice were elevated as the mice got older (from 5 weeks old to 15 weeks old). Serum levels of AGE were positively correlated with insulin (R2=0.3956, P=0.002) in KK-Ay mice. Administration of pyridoxamine dose-dependently decreased fasting insulin levels and improved insulin sensitivity in KK-Ay mice of 10 weeks old, although it did not affect fasting blood glucose levels. Our present study suggests the involvement of AGE in insulin resistance in KK-Ay mice. Inhibition of AGE formation may be a novel therapeutic target for improving insulin resistance in diabetes with obesity.
Keywords: AGE, insulin resistance, diabetes
Protein & Peptide Letters
Title: Pyridoxamine, an Inhibitor of Advanced Glycation End Product (AGE) Formation Ameliorates Insulin Resistance in Obese, Type 2 Diabetic Mice
Volume: 17 Issue: 9
Author(s): Hiroyuki Unoki-Kubota, Sho-ichi Yamagishi, Masayoshi Takeuchi, Hideaki Bujo and Yasushi Saito
Affiliation:
Keywords: AGE, insulin resistance, diabetes
Abstract: There is a growing body of evidence that the formation and accumulation of advanced glycation end products (AGE) have been known to progress under diabetic conditions, thereby being involved in diabetic vascular complications. Further, we, along with others, have recently found AGE could disturb insulin actions in cultured adipocytes and skeletal muscles. However, the pathological role of AGE in insulin resistance in vivo is not fully understood. Therefore, in this study, we examined whether pyridoxamine, an inhibitor of AGE formation could ameliorate insulin resistance in KK-Ay mice, a model animal of obese, type 2 diabetes. Fasting blood glucose, serum levels of insulin and AGE in KK-Ay mice were elevated as the mice got older (from 5 weeks old to 15 weeks old). Serum levels of AGE were positively correlated with insulin (R2=0.3956, P=0.002) in KK-Ay mice. Administration of pyridoxamine dose-dependently decreased fasting insulin levels and improved insulin sensitivity in KK-Ay mice of 10 weeks old, although it did not affect fasting blood glucose levels. Our present study suggests the involvement of AGE in insulin resistance in KK-Ay mice. Inhibition of AGE formation may be a novel therapeutic target for improving insulin resistance in diabetes with obesity.
Export Options
About this article
Cite this article as:
Unoki-Kubota Hiroyuki, Yamagishi Sho-ichi, Takeuchi Masayoshi, Bujo Hideaki and Saito Yasushi, Pyridoxamine, an Inhibitor of Advanced Glycation End Product (AGE) Formation Ameliorates Insulin Resistance in Obese, Type 2 Diabetic Mice, Protein & Peptide Letters 2010; 17 (9) . https://dx.doi.org/10.2174/092986610791760423
DOI https://dx.doi.org/10.2174/092986610791760423 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmacological and Clinical Applications of Natriuretic Peptides: Accepted Knowledges or Changing Views?
Current Pharmaceutical Analysis Streptozotocin-Induced Diabetes Mellitus in Neonatal Rats: An Insight into its Applications to Induce Diabetic Complications
Current Diabetes Reviews Intra-Renal Hemodynamic Changes After Habitual Physical Activity in Patients with Chronic Kidney Disease
Current Pharmaceutical Design Update on the Protective Renal Effects of Metformin in Diabetic Nephropathy
Current Medicinal Chemistry Decorin Biology, Expression, Function and Therapy in the Cornea
Current Molecular Medicine Nitrogen, Oxygen or Sulfur Containing Heterocyclic Compounds as Analgesic Drugs Used as Modulators of the Nitroxidative Stress
Mini-Reviews in Medicinal Chemistry Bitter Gourd (Momordica charantia) is a Cornucopia of Health: A Review of its Credited Antidiabetic, Anti-HIV, and Antitumor Properties
Current Molecular Medicine NF-κB and Proteinuric Renal Disease
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Natural AMPK Activators: An Alternative Approach for the Treatment and Management of Metabolic Syndrome
Current Medicinal Chemistry Protocatechuic Acid Alkyl Esters: Hydrophobicity As a Determinant Factor for Inhibition of NADPH Oxidase
Current Medicinal Chemistry Organoselenium Small Molecules and Chromium(III) Complexes for Intervention in Chronic Low-grade Inflammation and Type 2 Diabetes
Current Topics in Medicinal Chemistry A2A Receptor Ligands: Past, Present and Future Trends
Current Topics in Medicinal Chemistry “SLY AS A FOXO”: New Paths with Forkhead Signaling in the Brain
Current Neurovascular Research Non Peptidic Urotensin II Antagonists: Perspectives for a New Class of Drugs
Cardiovascular & Hematological Agents in Medicinal Chemistry High Sensitivity Troponin in Cardiovascular Disease. Is There More Than a Marker of Myocardial Death?
Current Topics in Medicinal Chemistry Editorial: [Hot Topic: Recent Developments in Biomarker Patenting for AKI]
Recent Patents on Biomarkers Update on AKI Biomarker Patents
Current Biomarkers (Discontinued) Periodontal Bacteria Aggravate Chronic Renal Failure Induced by Subtotal Nephrectomy in Mice
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Clinical Proteomics in Application to Predictive Diagnostics and Personalized Treatment of Diabetic Patients
Current Proteomics IgA Nephropathy: Clinical Significance of Urinary Proteins/Polypeptides Characterization
Current Proteomics